Trends in psychiatric hospitalization for alcohol and drugs in Castilla y León between 2005 and 2015. / Tendencias en la hospitalización psiquiátrica por alcohol y drogas en Castilla y León entre 2005 y 2015.

It has been estimated that alcohol, tobacco, and illicit drugs were responsible for more than 10 million deaths worldwide in 2016, and there are many opportunities for improvement. Regarding innovative data analysis, advances have been made in the extraction of information from administrative databases for analytics purposes. We studied trends in hospitalization rates for alcohol and drug abuse over eleven years with Joinpoint Trend Analysis software. This is a descriptive study of cross-associations in 3,758 hospital admissions of patients admitted with a main diagnosis of alcohol and drug abuse or dependence in psychiatry units of public health centres of Castilla y León (Spain) between 2005 and 2015. Hospitalization trends for alcohol and drug related conditions declined over the eleven-year period. Separately, there was a statistically significant decrease in alcohol and cocaine related conditions, but a strong upward trend in cannabis related conditions between 2013 and 2015. Alcohol was the main cause of admission to psychiatric units with a diagnosis of addiction. In the 11 years researched, there was a progressive and constant reduction in admissions for substance use except for cannabis. The innovative statistical methodology has already proven to be useful for identifying trends and changes in different pathologies over time.

A nivel mundial, se ha estimado que el alcohol, el tabaco y las drogas han sido responsables de más de 10 millones de muertes en 2016, y que existe mucho margen para reducir la mortalidad. Se han realizado avances en la extracción de información de bases de datos administrativas con el fin de analizar grandes volúmenes de datos sanitarios. Hemos estudiado las tendencias en las tasas de hospitalización con diagnóstico de adicción a alcohol y drogas durante once años con el software Joinpoint Trend Analysis. Se trata de un estudio descriptivo de asociación cruzada de 3.758 ingresos hospitalarios de pacientes con diagnóstico principal de abuso o dependencia de alcohol y drogas en unidades de Psiquiatría de centros públicos de Castilla y León entre 2005 y 2015. Las tendencias en la hospitalización por adicción al alcohol y/o drogas disminuyeron a lo largo de los once años. Además de una reducción estadísticamente significativa de los ingresos por alcohol y cocaína, se apreció una fuerte tendencia al alza en los ingresos por cannabis entre 2013 y 2015. El alcohol fue durante todo el periodo de estudio la principal causa de ingreso y el que más días de hospitalización ha generado. No obstante, en los 11 años se observó una reducción progresiva y constante en los ingresos por todas las sustancias a excepción del cannabis. La metodología utilizada ya ha demostrado ser muy útil para identificar cambios de tendencias en diferentes patologías.

Case Report: Pharmacogenetics Applied to Precision Psychiatry Could Explain the Outcome of a Patient With a New CYP2D6 Genotype.

Precision medicine applied to psychiatry provides new insight into the promising field of precision psychiatry. Psychotic disorders are heterogeneous, complex, chronic, and severe mental disorders. Not only does the prognosis and the course of the disease vary among patients suffering from psychotic disorders, but the treatment response varies as well. Although antipsychotic drugs are the cornerstone of the treatment of schizophrenia, many patients only partially respond to these drugs. Furthermore, patients often experience adverse events which can lead to poor treatment adherence. Interindividual variability in drug response could be related to age, gender, ethnicity, lifestyle factors, pharmacological interactions, obesity, and genetics, all of which influence the process of drug metabolism. Commonly prescribed antipsychotics are metabolized by cytochrome P450 (CYP450) enzymes, and CYP450 genes are highly polymorphic. Pharmacogenetic testing is increasingly being used to predict a patient's drug response and could help to find the most appropriate therapy for an individual patient. In this report, we describe a psychotic patient who did not receive adequate clinical follow-up and subsequently presented adverse events, which could be explained by his pharmacogenetic profile and the drug interactions resulting from the polypharmacy prescribed.

Impact of GSTA1 Polymorphisms on Busulfan Oral Clearance in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation.

BACKGROUND: Busulfan pharmacokinetics exhibit large inter-subject variability. Our objective was to evaluate the influence of glutathione S-transferase A1 (GSTA1) gene variants on busulfan oral clearance (CLo) in a population of patients undergoing hematopoietic stem cell transplantation. METHODS: This is a quasi-experimental retrospective study in adult patients (n = 87 included in the final analyses) receiving oral busulfan. Pharmacokinetics data (area under the plasma concentration-time curve (AUC) determined from 10 blood samples) were retrieved from patients' files and GSTA1 *A and *B allele polymorphisms determined from banked DNA samples. Three different limited sampling methods (LSM) using four blood samples were also compared. RESULTS: Carriers of GSTA1*B exhibited lower busulfan CLo than patients with an *A/*A genotype (p < 0.002): Busulfan CLo was 166 ± 31, 187 ± 37 vs. 207 ± 47 mL/min for GSTA1*B/*B, *A/*B and *A/*A genotypes, respectively. Similar results were obtained with the tested LSMs. Using the standard AUC method, distribution of patients above the therapeutic range after the first dose was 29% for GSTA1*A/*A, 50% for *A/*B, and 65% for *B/*B. The LSMs correctly identified ≥91% of patients with an AUC above the therapeutic range. The misclassified patients had a mean difference less than 5% in their AUCs. CONCLUSION: Patients carrying GSTA1 loss of function *B allele were at increased risk of overdosing on their initial busulfan oral dose. Genetic polymorphisms associated with GSTA1 explain a significant part of busulfan CLo variability which could be captured by LSM strategies.

Atención psicológica y Tecnologías: oportunidades y conflictos / Psychological care and Technologies: opportunities and conflicts

Los desarrollos tecnológicos pueden ser un complemento a la atención tradicional, por ello primero se revisa el impacto que tiene la tecnología en la alianza de trabajo terapéutico. A continuación se señalan algunos recursos tecnológicos disponibles para la actividad psicológica, así como una clasificación de las tecnologías. Finalmente se revisan las posibles ventajas y riesgos en la aplicación de tratamiento mediados por tecnologías, así como los resultados en cuanto a efectividad.

Every time new applications of information and communication technologies (ICTs) are developed for psychological care. This article aims to favor the implementation of technological applications in daily practice. To do so, some advantages of the use of technologies are pointed out and the impact of technology on the alliance of therapeutic work is reviewed. Secondly, some technological resources available for psychological work are pointed out, as well a classification of such technologies. This is followed by a review of the possible risks of the application of treatments mediated by technologies. Finally, the results in terms of effectiveness are indicated. All in all, the conclusion is that ICTs are tools whose effectiveness has been proven and they can be a complement to traditional care.

Evaluation of Limited Sampling Methods for Oral Busulfan Pharmacokinetic Monitoring in Adult Patients Undergoing Hematopoietic Stem Cell Transplantation.

BACKGROUND: Monitoring busulfan area under the plasma concentration-time curve (AUC) to establish the dose regimen for stem cell transplantation desirable to achieve efficacy while avoiding toxicity. OBJECTIVE: Our objective was to compare AUCs calculated by 18 limited sampling methods (LSMs) from 2 to 5 samples to reference AUCs determined from 10 samples in a retrospective study of 103 adult patients receiving oral busulfan. LSMs using 2 or 3 samples were ineffective. METHODS: Four LSMs using 4 or 5 blood samples that accurately characterized busulfan AUC were identified. The best 2 methods were obtained with sampling at 0.5, 1, 2, 4, and 6 hours and after 1, 1.5, 2, 4, and 6 hours postdose. For these LSMs, the incidence of 20% difference between AUCs from LSMs and reference AUCs was less than 1.3%. CONCLUSIONS: Effective and safe determination of AUC for oral busulfan can be made with strategies using only 4 or 5 concentration timepoints.